Logo

Marina Plans to Raise $1.2M in Stock Offering

Mar 22, 2012
Premium

Marina Biotech this week said that it plans to raise $1.2 million through the registered direct placement of common stock to certain institutional investors at $0.75 a share.

The company's stock has been trading recently around $0.68 a share.

Marina also said that it will issue the investors warrants to buy up to 800,000 shares of its stock at an exercise price of $0.75.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Marina
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.